Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GBM6-AD Vaccine + Poly-ICLC in Grade II Glioma
NCT02549833Phase 1Completed
- Start
- Oct 2016
- Primary completion
- Aug 2022
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of GBM6-AD lysate in glioma (2 arms). Primary endpoints: Regimen Limiting Toxicity up to 18 months and Vaccine-induced immune response in resected tumor. Started Oct 2016; status: completed.
02
Drugs
GBM6-AD lysate
03
Conditions
glioma
Beyond the preview
Go deeper on NCT02549833.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02549833.